Gamehaus reports Q3 2026 profit growth amid strategic pivot
Gamehaus Holdings (NASDAQ:GMHS) reported its unaudited financial results for the third quarter of fiscal year 2026, ended March 31, 2026.

Jon is a former international magazine editor with a strong background in business publications (print and digital) in the Middle East and Australia.
Gamehaus Holdings (NASDAQ:GMHS) reported its unaudited financial results for the third quarter of fiscal year 2026, ended March 31, 2026.
Nurix Therapeutics (NASDAQ:NRIX) announced on June 8, 2026, that it has entered into a global licensing and collaboration agreement with Roche to co-develop and co-commercialize bexobrutideg (NX-5948).
XRP has rebounded from four-month lows after buyers stepped in around the $1.09 level, helping the token recover from one of its steepest declines of the year while broader market sentiment remains fragile.
Solana co-founder Anatoly Yakovenko has publicly rejected Senator Bernie Sanders' warning that artificial intelligence and robotics could destroy millions of American jobs, reigniting debate over automation, wealth creation and the future of work.
Crypto exchange HTX has removed support for the USD1 stablecoin issued by World Liberty Financial, alleging the platform froze several exchange-linked blockchain addresses without proper justification.
Vitura Health (ASX:VIT) announced the immediate appointment of Tom Howitt as interim CFO.
Iran is reportedly collecting between $1.5 million and $2 million from vessels passing through the Strait of Hormuz, with some payments allegedly being settled using USDT rather than cash or barter arrangements.
Iran launched a major missile bombardment at Israel, shattering a fragile two-month ceasefire and stoking fears of a full-scale regional conflict.
Abra is positioning itself as a tokenisation and digital wealth management platform as it prepares for a Nasdaq listing and expands beyond its roots in crypto trading and custody.
Edesa Biotech (NASDAQ:EDSA) announced favorable exploratory findings for its lead therapeutic candidate, paridiprubart, in patients suffering from acute kidney injury (AKI) and concurrent respiratory distress.
Got a second for a cookie? 🍪Essential cookies keep Grafa running smoothly. A few optional ones help us see what's working so we can make it better. You're in control — change your mind any time. Cookie policy · Privacy policy